A Retrospective, Cross-sectional Study Evaluating Plasma Neurofilament Light Levels in Autoimmune Encephalitis (2553)

摘要: Objective: To evaluate plasma neurofilament light (NfL) levels in autoimmune encephalitis (AE). Background: Despite an incidence rate of 0.8/100,000 person-years AE, individual antibody syndromes are rare. Each particular syndrome has a different clinical phenotype, making one unifying outcome measure difficult to assess as group. However, the final common pathway is neuronal damage, suggesting that NfL may be biomarker central nervous system injury easily obtainable through blood and demonstrate quantitative treatment response. promising for predicting disease activity other inflammatory diseases such relapsing-remitting multiple sclerosis, but this not been well studied AE. Design/Methods: Patients were retrospectively identified who enrolled biorepository at Rocky Mountain MS Center University Colorado. had well-defined neurological followed between 2014 2019. was tested using Single Molecule Array (SIMOA) technology (Quanterix). Levels >10 pg/ml considered positive values based on normative control data. Results: Twenty 8 CSF samples stored evaluated. Elevated seen patients with various types AE: glial fibrillary acidic protein (GFAP), glutamic acid decarboxylase (GAD)-65, leucine-rich glioma-inactivated (LGI1), glycine receptor, N-methyl-D-aspartate (NMDA) receptor antibodies. Higher found untreated, acute presentations subjects active symptoms. Six seven >10pg/ml presented acutely. within 6 months presentation higher (17.6+/−22.4pg/ml) than those farther out from (5.8+/−7.3pg/ml)(p=0.025) There correlation (r=0.74) mean 39pg/ml CSF. Conclusions: Our findings support use potential non-invasive antibody-mediated Disclosure: Dr. Piquet received personal compensation consulting, serving scientific advisory board, speaking, or activities Sanofi Genzyme honorarium MedLink. research Drake Family Children’s Hospital Colorado Foundation funding Center.. Alvarez consulting fees Actelion, Bayer, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, TG Therapeutics. Therapeutics, Center.Dr. Bennett Alexion, Chugai, Clene Nanomedicine, Equillium, Frequency Roche, MedImmune/Viela Bio, Novartis. royalty, license fees, contractual rights payments Aquaporumab. Novartis.Dr. Knapp nothing disclose. Sillau Nair Gilead. Biogen.Dr. Vollmer Biogen Idec, Genentech-Roche, Siranax, Center, F. Hoffman -La